Can personalised medicine save the pharma sector?
17 March 2011 | By GDS International
Personalised medicine is making a comeback – but will it stick this time?...
List view / Grid view
17 March 2011 | By GDS International
Personalised medicine is making a comeback – but will it stick this time?...
2 March 2011 | By Roche
Avastin in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe...
21 February 2011 | By Roche
Role will focus on disorders such as schizophrenia, neurodegeneration, treatment-resistant depression & neurodevelopment...
16 February 2011 | By Roche
The phase III study will investigate a subcutaneous formulation of MabThera for patients with non-Hodgkin’s lymphoma...
14 February 2011 | By GDS International
What are the strategies for reducing drug attrition rates in the clinic through the application of transgenic rodent models?...
31 January 2011 | By Roche
Roche announced that the U.S. FDA approved Rituxan/MabThera as a maintenance treatment for patients with advanced follicular lymphoma...
17 January 2011 | By Roche
Erich Hunziker, Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011...
6 December 2010 | By F. Hoffmann-La Roche Ltd
Roche today presented eight-week results from a phase II study of RG16781...
23 November 2010 | By F. Hoffmann-La Roche Ltd
Roche obtained a worldwide sublicense from Genzyme Corporation to develop a diagnostic assay for the detection of EGFR mutations...
10 September 2010 | By NG Online News
Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?
20 March 2009 | By
Generating knowledge and insight from complex genomic data sets is always a challenging endeavor. As data collection becomes more routine and less expensive, and the existing body of data expands, getting the most out of genomics experiments requires ever more expertise and insight. Here, we discuss our method of integrating…